Triple-negative Breast Cancer: New Perspectives for Novel Therapies

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2013 Jul 5

PMID 23824643

Citations 17

Authors

Yashin A Mahamodhossen

Wei Liu

Zhou Rong-Rong

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) represents 10-20 % of all mammary tumors. It is often found in younger women and has been associated with poor prognosis, due to aggressive tumor phenotype(s), early metastasis to visceral organ or brain after chemotherapy and present lack of clinically established targeted therapies. In recent years, a greater understanding of the biology of this disease has led to the development of numerous and varied therapeutic approaches, especially the trials on poly (ADP-ribose) polymerase inhibitors BSI-201 and olaparib, and antiangiogenic agents such as bevacizumab and sunitinib, which have raised hopes in the treatment for TNBC and BRCA1/2-positive disease. But should these trials fail, what are the new possible perspectives we have in our hand to fight this disease? In the current review, we will assess mainly the possible future targeted therapeutic strategies, which could be the answer to our question in TNBC. Recent studies have shown several markers, which have roles in TNBC that could be possible targets for therapy. Some of these markers are p53-induced miR-205, leptin receptor antagonist peptide, enhancer of zeste homolog 2 and Notch 1 pathway components, each of them could offer different mechanism for target therapy in TNBC. Last but not least, vaccinia virus GLV-1h153 has shown exciting result in treating and preventing metastatic triple-negative breast cancer.

Citing Articles

A feedback loop between lncRNA MALAT1 and DNMT1 promotes triple-negative breast cancer stemness and tumorigenesis.

Hu Y, He Y, Luo N, Li X, Guo L, Zhang K Cancer Biol Ther. 2023; 24(1):2235768.

PMID: 37548553 PMC: 10408694. DOI: 10.1080/15384047.2023.2235768.

WTAP Mediates NUPR1 Regulation of LCN2 Through mA Modification to Influence Ferroptosis, Thereby Promoting Breast Cancer Proliferation, Migration and Invasion.

Tan M, He Y, Yi J, Chen J, Guo Q, Liao N Biochem Genet. 2023; 62(2):876-891.

PMID: 37477758 DOI: 10.1007/s10528-023-10423-8.

Development of a 15-Gene Signature Model as a Prognostic Tool in Sex Hormone-Dependent Cancers.

Xia Z, Xiao J, Liu A, Chen Q Biomed Res Int. 2021; 2021:3676107.

PMID: 34869761 PMC: 8635877. DOI: 10.1155/2021/3676107.

YAP1/MMP7/CXCL16 axis affects efficacy of neoadjuvant chemotherapy via tumor environment immunosuppression in triple-negative breast cancer.

Yuan J, Zhang K, Wang S, Guo L Gland Surg. 2021; 10(9):2799-2814.

PMID: 34733729 PMC: 8514296. DOI: 10.21037/gs-21-612.

Effects of CORO2A on Cell Migration and Proliferation and Its Potential Regulatory Network in Breast Cancer.

Deng J, Zhang H, Zeng Y, Xu Y, Huang Y, Wang G Front Oncol. 2020; 10:916.

PMID: 32695665 PMC: 7333780. DOI: 10.3389/fonc.2020.00916.

References

Iorio M, Croce C . MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-56. PMC: 2793003. DOI: 10.1200/JCO.2009.24.0317. View

von Drygalski A, Tran T, Messer K, Pu M, Corringham S, Nelson C . Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int J Breast Cancer. 2012; 2011:523276. PMC: 3262587. DOI: 10.4061/2011/523276. View

Wang M, Wu L, Wang L, Xin X . Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun. 2010; 393(1):144-9. DOI: 10.1016/j.bbrc.2010.01.103. View

Chen J, Russo J . ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta. 2009; 1796(2):162-75. PMC: 2937358. DOI: 10.1016/j.bbcan.2009.06.003. View

Lu C, Han H, Mangala L, Ali-Fehmi R, Newton C, Ozbun L . Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010; 18(2):185-97. PMC: 2923653. DOI: 10.1016/j.ccr.2010.06.016. View

Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G . Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012; 6(4):458-72. PMC: 3679926. DOI: 10.1016/j.molonc.2012.03.003. View

Polager S, Ginsberg D . p53 and E2f: partners in life and death. Nat Rev Cancer. 2009; 9(10):738-48. DOI: 10.1038/nrc2718. View

Hussein Y, Sood A, Bandyopadhyay S, Albashiti B, Semaan A, Nahleh Z . Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012; 43(10):1638-44. PMC: 4194857. DOI: 10.1016/j.humpath.2011.12.004. View

Amir E, Cecchini R, Ganz P, Costantino J, Beddows S, Hood N . 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. Breast Cancer Res Treat. 2012; 133(3):1077-88. PMC: 3396331. DOI: 10.1007/s10549-012-2012-x. View

10.

Alam S, Bowser B, Conway M, Israr M, Tandon A, Meyers C . Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Mol Cancer. 2011; 10:97. PMC: 3199901. DOI: 10.1186/1476-4598-10-97. View

11.

Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymer I . Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. Cancer Lett. 2012; 328(2):261-70. DOI: 10.1016/j.canlet.2012.09.023. View

12.

Sivendran S, Pan M, Kaufman H, Saenger Y . Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther. 2010; 10(7):1145-53. DOI: 10.1517/14712598.2010.495383. View

13.

Swede H, Gregorio D, Tannenbaum S, A Brockmeyer J, Ambrosone C, Wilson L . Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study. Clin Breast Cancer. 2011; 11(5):332-41. PMC: 4459583. DOI: 10.1016/j.clbc.2011.04.004. View

14.

Singh P, Kapil U, Shukla N, Deo S, Dwivedi S . Association of overweight and obesity with breast cancer in India. Indian J Community Med. 2012; 36(4):259-62. PMC: 3263144. DOI: 10.4103/0970-0218.91326. View

15.

Ray A, Cleary M . Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets. 2010; 14(4):443-51. DOI: 10.1517/14728221003716466. View

16.

Eskander R, Ji T, Huynh B, Wardeh R, Randall L, Hoang B . Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer. 2013; 23(6):997-1005. PMC: 3694282. DOI: 10.1097/IGC.0b013e318296a265. View

17.

Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin S . Treatment of breast cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther. 2012; 19(10):707-14. PMC: 3444761. DOI: 10.1038/cgt.2012.49. View

18.

Wu H, Mo Y . Targeting miR-205 in breast cancer. Expert Opin Ther Targets. 2009; 13(12):1439-48. DOI: 10.1517/14728220903338777. View

19.

Cao Q, Mani R, Ateeq B, Dhanasekaran S, Asangani I, Prensner J . Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell. 2011; 20(2):187-99. PMC: 3157014. DOI: 10.1016/j.ccr.2011.06.016. View

20.

Oh S, Park C, Lee E, Yoon Y, Lee E, Park S . Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res. 2011; 13(2):R34. PMC: 3219197. DOI: 10.1186/bcr2856. View